A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads

Cooler Heads

Status

Withdrawn

Conditions

Breast Cancer

Hair Loss

Alopecia

Gynecologic Cancer

Chemotherapy-induced Alopecia

Treatments

Device: AMMA Portalbe Scalp Cooling System

Study type

Interventional

Funder types

Other

Identifiers

NCT05365243

WPH 2201

Details and patient eligibility

About

Eligible patients will be recruited prior to initiation of chemotherapy for any stage breast or gynecologic cancer. Patients will undergo training in the use of the AMMA Portable Scalp Cooling System and will use the device during each of their chemotherapy treatments. Quality of life and experience of use questionnaires will be completed. Scalp photos and an assessment of hair loss will be preformed at enrollment and at the end of study participation.

Full description

AMMA is designed to be used by patients in the chemotherapy infusion center, during transport from the infusion center to home, and after arrival at home. Patients will participate in training in AMMA use and will be asked to bring the device to the chemotherapy infusion center for use during each chemotherapy treatment visit. The device will be used for 30 minutes prior to the start of chemotherapy, during chemotherapy and for 2 hours after chemotherapy. Scalp photos will be obtained at baseline and after the last chemotherapy treatment. Patients will be asked to complete the following questionnaires: training evaluation after training is complete; and symptoms from device use, experience with device use and self-assessment of hair loss after each chemotherapy treatment.

Sex

Female

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Female age 21 years or older at the time of signing informed consent.
Documented pathologic diagnosis of invasive breast or gynecologic cancer, any stage, requiring treatment with a taxane-containing chemotherapy regimen
Planned start of treatment with taxane-based chemotherapy in the adjuvant, neoadjuvant or advanced setting
Plan to complete chemotherapy within 6 months of treatment start
If received prior chemotherapy causing hair loss, >/= 2 years since last chemotherapy dose and complete recovery of hair
ECOG performance status 0-1
Willing and able to sign informed consent for study procedures
Willing and able to participate in all study procedures

Exclusion criteria

Plan to use chemotherapy regimen other than that listed in inclusion criteria, including any anthracycline-based regimen
Plan to initiate bone marrow ablation chemotherapy
History of or plan to initiate whole or partial brain or skull irradiation
Hormone therapy concurrent with current chemotherapy regimen
Existing or suspected scalp metastases
History of concomitant diagnosis of: autoimmune disease affecting hair; cryoglobulinemia; untreated iron deficiency with or without anemia; cold agglutination disease; post-traumatic cold dystrophy; untreated or poorly controlled hyper- or hypothyroidism
Female pattern baldness
History of persistent chemotherapy-induced alopecia from prior chemotherapy
Concomitant exposure to investigational agents, drugs, devices or procedures that cause hair loss
Concomitant other solid tumor or hematologic malignancy in addition to the current diagnosis